chr8-86667134-C-G
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000320005.6(CNGB3):c.644-1G>C variant causes a splice acceptor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000018 in 1,613,178 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
ENST00000320005.6 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CNGB3 | NM_019098.5 | c.644-1G>C | splice_acceptor_variant | ENST00000320005.6 | NP_061971.3 | |||
CNGB3 | XM_011517138.3 | c.230-1G>C | splice_acceptor_variant | XP_011515440.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CNGB3 | ENST00000320005.6 | c.644-1G>C | splice_acceptor_variant | 1 | NM_019098.5 | ENSP00000316605 | P1 | |||
CNGB3 | ENST00000681746.1 | c.644-1G>C | splice_acceptor_variant, NMD_transcript_variant | ENSP00000505959 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152148Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000399 AC: 10AN: 250676Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135446
GnomAD4 exome AF: 0.0000178 AC: 26AN: 1461030Hom.: 0 Cov.: 34 AF XY: 0.0000165 AC XY: 12AN XY: 726820
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152148Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74308
ClinVar
Submissions by phenotype
Achromatopsia 3 Pathogenic:3
Pathogenic, no assertion criteria provided | research | Molecular Genetics Laboratory, Institute for Ophthalmic Research | Mar 27, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 18, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | May 12, 2014 | - - |
Achromatopsia Pathogenic:2
Pathogenic, no assertion criteria provided | research | Sharon lab, Hadassah-Hebrew University Medical Center | Jun 23, 2019 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 20, 2024 | This sequence change affects an acceptor splice site in intron 5 of the CNGB3 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CNGB3 are known to be pathogenic (PMID: 28795510). This variant is present in population databases (rs201794629, gnomAD 0.09%). Disruption of this splice site has been observed in individuals with achromatopsia (PMID: 15657609, 25616768, 28795510). ClinVar contains an entry for this variant (Variation ID: 188780). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 06, 2020 | Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 31456290, 28795510, 25616768, 15657609, 31544997) - |
CNGB3-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 26, 2024 | The CNGB3 c.644-1G>C variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant was reported in individuals with achromatopsia (Kohl et al. 2005. PubMed ID: 15657609; Table S2, Sharon et al. 2019. PubMed ID: 31456290). This variant is reported in 0.097% of alleles in individuals of Ashkenazi Jewish descent in gnomAD. Variants that disrupt the consensus splice acceptor site in CNGB3 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Retinitis pigmentosa;C1849792:Achromatopsia 3;C1855465:Severe early-childhood-onset retinal dystrophy Other:1
not provided, no classification provided | phenotyping only | GenomeConnect - Invitae Patient Insights Network | - | Variant interpreted as Pathogenic and reported on 02-21-2020 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at